Botulinum toxin as an adjuvant option in the treatment of neuropathic pain in the face

Authors

DOI:

https://doi.org/10.33448/rsd-v12i13.44372

Keywords:

Face; Botulinum toxins, type A; Facial nerve diseases.

Abstract

Botulinum toxin, derived from the Clostridium botulinum bacterium, has a multifaceted history, initially recognized for causing foodborne intoxications and more recently standing out for its therapeutic applications. Its mechanism of action, inhibiting the release of acetylcholine at neuromuscular junctions, results in temporary muscle paralysis, widely used in aesthetics to smooth wrinkles and enhance facial contours. Additionally, botulinum toxin has shown efficacy as an adjuvant in the treatment of facial neuropathic pain, providing relief to patients with conditions such as trigeminal neuralgia. The literature narrative review aims to deepen the understanding of this therapeutic application, analyzing clinical studies and systematic reviews to assess its effectiveness, safety, and mechanisms of action. The objective is to explore and consolidate the available evidence, identifying gaps in current knowledge and providing insights to guide future research and clinical practices in this specific field.

References

Bellows, S., & Jankovic, J. (2019). Immunogenicity Associated with Botulinum Toxin Treatment. Toxins, 11(9), 491.

Borba, A., Matayoshi, S., & Rodrigues, M. (2022). Avoiding Complications on the Upper Face Treatment With Botulinum Toxin: A Practical Guide. Aesthetic plastic surgery, 46(1), 385–394.

Bouhassira D. (2019). Neuropathic pain: Definition, assessment and epidemiology. Revue neurologique, 175(1-2), 16–25.

Choudhury, S., Baker, M. R., Chatterjee, S., & Kumar, H. (2021). Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins, 13(1), 58.

Dressler, D., Adib Saberi, F., & Rosales, R. L. (2021). Botulinum toxin therapy of dystonia. Journal of neural transmission, 128(4), 531–537.

Fernández-Núñez, T., Amghar-Maach, S., & Gay-Escoda, C. (2019). Efficacy of botulinum toxin in the treatment of bruxism: Systematic review. Medicina oral, patologia oral y cirugia bucal, 24(4), e416–e424.

Finnerup, N. B., Kuner, R., & Jensen, T. S. (2021). Neuropathic Pain: From Mechanisms to Treatment. Physiological reviews, 101(1), 259–301.

Gutierre, T. C. M., Suguihara, R. T., & Muknicka, D. P. (2023). Therapeutic botulinum toxin in orofacial harmonization. Research, Society and Development, 12(12), e113121244066.

Matak, I., Bölcskei, K., Bach-Rojecky, L., & Helyes, Z. (2019). Mechanisms of Botulinum Toxin Type A Action on Pain. Toxins, 11(8), 459.

Moisset, X., Bouhassira, D., & Attal, N. (2021). French guidelines for neuropathic pain: An update and commentary. Revue neurologique, 177(7), 834–837.

Rodrigues, G. P. L., Suguihara, R. T., & Muknicka, D. P. (2023). Parafunctional habits and botulinum toxin: A narrative review of the literature. Research, Society and Development, 12(12), e18121243908.

Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., & Treede, R. D. (2020). Challenges of neuropathic pain: focus on diabetic neuropathy. Journal of neural transmission, 127(4), 589–624.

Rother, E. T. (2007). Revisão sistemática x revisão narrativa. Acta Paul. Enferm, 20(2).

Scholz, J., Finnerup, N. B., Attal, N., Aziz, Q., Baron, R., Bennett, M. I., Benoliel, R., Cohen, M., Cruccu, G., Davis, K. D., Evers, S., First, M., Giamberardino, M. A., Hansson, P., Kaasa, S., Korwisi, B., Kosek, E., Lavand'homme, P., Nicholas, M., Nurmikko, T., & Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG) (2019). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain, 160(1), 53–59.

Serrera-Figallo, M. A., Ruiz-de-León-Hernández, G., Torres-Lagares, D., Castro-Araya, A., Torres-Ferrerosa, O., Hernández-Pacheco, E., & Gutierrez-Perez, J. L. (2020). Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins, 12(2), 112.

Solish, N., Carruthers, J., Kaufman, J., Rubio, R. G., Gross, T. M., & Gallagher, C. J. (2021). Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A. Drugs, 81(18), 2091–2101.

Souza, V. C. M., Suguihara, R. T., & Muknicka, D. P. (2023). Botulinum toxin in the control of bruxism. Research, Society and Development, 12(11), e135121143879.

Spagna, A., & Attal, N. (2023). Botulinum toxin A and neuropathic pain: An update. Toxicon, 232, 107208.

Szok, D., Tajti, J., Nyári, A., & Vécsei, L. (2019). Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behavioural neurology, 2019, 8685954.

Vieira, A. A. De P., Suguihara, R. T., & Muknicka, D. P. (2023). Coadjuvant treatment of botulinum toxin in bruxism. Research, Society and Development, 12(8), e1512842852.

Published

06/12/2023

How to Cite

HUAMANI, F. H. V. G. .; SUGUIHARA, R. T. .; MUKNICKA, D. P. . Botulinum toxin as an adjuvant option in the treatment of neuropathic pain in the face. Research, Society and Development, [S. l.], v. 12, n. 13, p. e112121344372, 2023. DOI: 10.33448/rsd-v12i13.44372. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/44372. Acesso em: 31 oct. 2024.

Issue

Section

Health Sciences